Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula
January 5, 2024
- Moderna Seeks Japan Nod for Pre-Filled Syringe Form of COVID Vaccine
January 5, 2024
- After GCP Scandal, Medipharma Begins Bankruptcy Proceedings
January 5, 2024
- Astellas, China Biotech Hook Up on Bispecific Macrophage Engagers
January 5, 2024
- South Korean Partner to Locally Manufacture Xocova: Shionogi
December 28, 2023
- Healios, Nobelpharma Ink Basic Deal for Cell Therapy Alliance in ARDS
December 28, 2023
- Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
- Eisai, Oita University Develop Wearable Sensor to Predict Brain Aβ Buildup
December 27, 2023
- iPSC-Based Parkinson’s Therapy Cleared for Investigator-Led Trial in US: Sumitomo
December 27, 2023
- Daiichi’s HER3 ADC Gets Priority Review in US for 3rd Line EGFR-Mutated NSCLC
December 26, 2023
- Mochida Files Label Expansion for Inhaled Treprost in Japan
December 26, 2023
- Sandoz to Take Over Distribution Rights to Japan’s 1st Humira Biosimilar
December 26, 2023
- Manabu Chikumoto to Helm Mitsubishi Chemical Group from April
December 25, 2023
- Rune Ejler Andersen Tapped as Japan Chief of Lundbeck
December 25, 2023
- Astellas Closes Buyout of US Prostate Cancer Drug Maker Propella
December 25, 2023
- Meiji’s Kostaive Booster Dose Non-Inferior to Pfizer COVID Jab: PIII Data
December 25, 2023
- Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
- AGC Invests 50 Billion Yen to Expand Biologics Production
December 22, 2023
- Mitsubishi Tanabe Sells Entire Stake in China JV to Local Firm
December 22, 2023
- Nippon Shinyaku’s DMD Med Snags Orphan Status in Europe
December 22, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…